9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Estimated reading time: < 1 min

Condition: Cancer

Estimated Enrollment: 130

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: Has Results

Outcome Measures: Summed Pain Intensity Differences (SPID) at 30 Minutes After Dosing (SPID30),  Summed Pain Intensity Differences (SPID) at 5, 10, 15, 45, and 60 Minutes After Dosing,  Total Pain Relief (TOTPAR) at 5, 10, 15, 30, 45, and 60 Minutes After Dosing, Global Evaluation of the Study Medication at 30 and 60 Minutes After Dosing

Interventions: Fentanyl sublingual spray, Placebo

Phase:

Study Type: Interventional

Study Design: Intervention Model: Crossover Assignment, Masking: Triple (Participant, Investigator, Outcomes Assessor), Primary Purpose: Treatment,

Primary Completion Date: February 2010

Completion Date: October 2010

Last  Posted Date: March 5, 2014

Location: InSys Therapeutics, Incorporated, Chandler, Arizona, United States

Website Link: https://ClinicalTrials.gov/show/NCT00538850

Was this article helpful?
Dislike 0